150 related articles for article (PubMed ID: 9551765)
1. Deramciclane, a putative anxiolytic drug, is a serotonin 5-HT2C receptor inverse agonist but fails to induce 5-HT2C receptor down-regulation.
Pälvimäki EP; Majasuo H; Kuoppamäki M; Männistö PT; Syvälahti E; Hietala J
Psychopharmacology (Berl); 1998 Mar; 136(2):99-104. PubMed ID: 9551765
[TBL] [Abstract][Full Text] [Related]
2. Sertindole is a serotonin 5-HT2c inverse agonist and decreases agonist but not antagonist binding to 5-HT2c receptors after chronic treatment.
Hietala J; Kuonnamäki M; Pälvimäki EP; Laakso A; Majasuo H; Syvälahti E
Psychopharmacology (Berl); 2001 Sep; 157(2):180-7. PubMed ID: 11594443
[TBL] [Abstract][Full Text] [Related]
3. Regulation of serotonin 5-HT2C receptors in the rat choroid plexus after acute clozapine treatment.
Kuoppamäki M; Seppälä T; Syvälahti E; Hietala J
Eur J Pharmacol; 1994 Oct; 269(2):201-8. PubMed ID: 7851496
[TBL] [Abstract][Full Text] [Related]
4. Combined treatment with citalopram and buspirone: effects on serotonin 5-HT2A and 5-HT2C receptors in the rat brain.
Syvälahti E; Penttilä J; Majasuo H; Pälvimäki EP; Laakso A; Hietala J
Pharmacopsychiatry; 2006 Jan; 39(1):1-8. PubMed ID: 16453246
[TBL] [Abstract][Full Text] [Related]
5. Deramciclane (Egis).
Kõks S; Vasar E
Curr Opin Investig Drugs; 2002 Feb; 3(2):289-94. PubMed ID: 12020062
[TBL] [Abstract][Full Text] [Related]
6. Differential regulation of rat 5-HT2A and 5-HT2C receptors after chronic treatment with clozapine, chlorpromazine and three putative atypical antipsychotic drugs.
Kuoppamäki M; Pälvimäki EP; Hietala J; Syvälahti E
Neuropsychopharmacology; 1995 Oct; 13(2):139-50. PubMed ID: 8597525
[TBL] [Abstract][Full Text] [Related]
7. Brain 5-HT2A receptor occupancy of deramciclane in humans after a single oral administration--a positron emission tomography study.
Kanerva H; Vilkman H; Någren K; Kilkku O; Kuoppamäki M; Syvälahti E; Hietala J
Psychopharmacology (Berl); 1999 Jul; 145(1):76-81. PubMed ID: 10445375
[TBL] [Abstract][Full Text] [Related]
8. The serotonin 5-HT2C receptor is a prominent serotonin receptor in basal ganglia: evidence from functional studies on serotonin-mediated phosphoinositide hydrolysis.
Wolf WA; Schutz LJ
J Neurochem; 1997 Oct; 69(4):1449-58. PubMed ID: 9326273
[TBL] [Abstract][Full Text] [Related]
9. Agonist properties of N,N-dimethyltryptamine at serotonin 5-HT2A and 5-HT2C receptors.
Smith RL; Canton H; Barrett RJ; Sanders-Bush E
Pharmacol Biochem Behav; 1998 Nov; 61(3):323-30. PubMed ID: 9768567
[TBL] [Abstract][Full Text] [Related]
10. Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503.
Rosenzweig-Lipson S; Zhang J; Mazandarani H; Harrison BL; Sabb A; Sabalski J; Stack G; Welmaker G; Barrett JE; Dunlop J
Brain Res; 2006 Feb; 1073-1074():240-51. PubMed ID: 16430874
[TBL] [Abstract][Full Text] [Related]
11. Different regulation of rat 5-HT(2A) and rat 5-HT(2C) receptors in NIH 3T3 cells upon exposure to 5-HT and pipamperone.
Oekelen DV; Jurzak M; Van de Wiel D; Van Hecke G; Luyten WH; Leysen JE
Eur J Pharmacol; 2001 Aug; 425(1):21-32. PubMed ID: 11672571
[TBL] [Abstract][Full Text] [Related]
12. Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor.
Pälvimäki EP; Roth BL; Majasuo H; Laakso A; Kuoppamäki M; Syvälahti E; Hietala J
Psychopharmacology (Berl); 1996 Aug; 126(3):234-40. PubMed ID: 8876023
[TBL] [Abstract][Full Text] [Related]
13. Functional study of rat 5-HT2A receptors using antisense oligonucleotides.
Van Oekelen D; Megens A; Meert T; Luyten WH; Leysen JE
J Neurochem; 2003 Jun; 85(5):1087-100. PubMed ID: 12753068
[TBL] [Abstract][Full Text] [Related]
14. Serotonin 5-HT2C receptor-mediated phosphoinositide hydrolysis in rat choroid plexus after fluoxetine and citalopram treatments.
Pälvimäki EP; Majasuo H; Syvälahti E; Hietala J
Pharmacol Res; 2005 May; 51(5):419-25. PubMed ID: 15749456
[TBL] [Abstract][Full Text] [Related]
15. Brain region-specific alterations of 5-HT2A and 5-HT2C receptors in serotonin transporter knockout mice.
Li Q; Wichems CH; Ma L; Van de Kar LD; Garcia F; Murphy DL
J Neurochem; 2003 Mar; 84(6):1256-65. PubMed ID: 12614326
[TBL] [Abstract][Full Text] [Related]
16. Effect of deramciclane, a new 5-HT receptor antagonist, on cholecystokinin-induced changes in rat gastrointestinal function.
Varga G; Kordás K; Burghardt B; Gacsályi I; Szénási G
Eur J Pharmacol; 1999 Feb; 367(2-3):315-23. PubMed ID: 10079007
[TBL] [Abstract][Full Text] [Related]
17. Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes.
Song J; Hanniford D; Doucette C; Graham E; Poole MF; Ting A; Sherf B; Harrington J; Brunden K; Stricker-Krongrad A
Assay Drug Dev Technol; 2005 Dec; 3(6):649-59. PubMed ID: 16438660
[TBL] [Abstract][Full Text] [Related]
18. Developmental switch in the hippocampal serotonin receptor linked to phosphoinositide hydrolysis.
Ike J; Canton H; Sanders-Bush E
Brain Res; 1995 Apr; 678(1-2):49-54. PubMed ID: 7620898
[TBL] [Abstract][Full Text] [Related]
19. High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action.
Fitzgerald LW; Conklin DS; Krause CM; Marshall AP; Patterson JP; Tran DP; Iyer G; Kostich WA; Largent BL; Hartig PR
J Neurochem; 1999 May; 72(5):2127-34. PubMed ID: 10217294
[TBL] [Abstract][Full Text] [Related]
20. Discovering the mechanisms underlying serotonin (5-HT)2A and 5-HT2C receptor regulation following nicotine withdrawal in rats.
Zaniewska M; Alenina N; Wydra K; Fröhler S; Kuśmider M; McCreary AC; Chen W; Bader M; Filip M
J Neurochem; 2015 Aug; 134(4):704-16. PubMed ID: 26031442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
